AACR 2024 | The future of peptide-conjugated drugs in oncology

Mitchell Elliott, MD, UHN Princess Margaret Cancer Centre, Toronto, Canada, comments on the emerging role of peptide-conjugated drugs in treating solid tumors. Whilst antibody-drug conjugates have proven to be successful in many indications, novel strategies are needed in patients who progress on them. Peptide-conjugated drugs have shown to be more successful in penetrating the tumor microenvironment, and sortilin has been identified as a promising target that facilitates rapid uptake of the payload. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.